Scale -


  • Revenue is 8373 Rs Cr; Annual Growth is 19 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 21 %
  • Ebitda is 2405 Rs Cr; Annual Growth is 20 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 22 %
  • PBT is 436 Rs Cr; Annual Growth is 19 %; in Top Quartile; 5 Year CAGR is 23 %
  • PAT is 1442 Rs Cr; Annual Growth is 34 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 24 %
  • Quarterly Revenue is 2366 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile

Profitability -


  • PAT Margin is 17.22 %; Annual Growth is 13 %; in Top Quartile
  • Quarterly Profit margin is 14 %; in Top Quartile

Return -


  • Asset Turnover is 52 %; 5 Year CAGR is 24 %; in Bottom Quartile

Efficiency -


  • Inventory Turnover Ratio is 75.95; Continuous Growth over 3 years; in Top Quartile
  • Operating cash flow is 1633 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 22 %
  • Current Ratio is 0.89; in Bottom Quartile
  • Quick Ratio is 0.84; in Bottom Quartile

Solvancy -


  • Long term Debt is 2439 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 40 %
  • Total Debt is 2907 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 41 %
  • Contingent Liabilities is 1479 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 30 %
  • Debt/Equity is 0.27; 5 Year CAGR is 22 %

Quality -


  • Current Tax/PAT is 15 %; Annual Decline is -53 %; in Bottom Quartile
  • Exceptional Items/PBT is -3 %; in Bottom Quartile; Annual Growth is 45 %
  • Other Expenses/Total Expenses is 17 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is 0 %; Annual Growth is 62 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
India's Max Healthcare posts lower quarterly profit on higher tax expenses
Max Healthcare Approves ?190 Cr Expansion for Hospitals
Max Healthcare Institute allots 16,803 equity shares under ESOP 2022
Max Healthcare MAXHEALTH Board Meeting October 2026
Max Healthcare Q2 PAT Up 10% to ?448 Cr; Revenue Rises 20%
Max Healthcare Q2 Results: Consolidated PAT falls 15% to Rs 414 crore; revenue rises 20% YoY
Max Healthcare Q2 results: Higher patient volumes lift revenue 20%, profit rises 10% to ?448 crore
Max Healthcare Q2 revenue rises to ? 3,219 Cr, profit at ? 448 Cr
Max Healthcare Q2FY27 Results: Revenue rises 21.8% YoY to ?2,569 crore
Max Healthcare quarterly profit falls as tax benefit fades in India
Max Healthcare Reports 10% PAT Jump To ?448 Crore In Q2, With Revenue Climbing 20% To ?3,219 Crore;
Max Healthcare Reports Q2 Consolidated Net Profit Of ?4.15 Billion Versus ?4.9 Billion YoY
Max Healthcare shares close higher as Q2 revenue rises 20%
Max Healthcare Subsidiary Kalinga Hospital Faces NCLT Proceedings; Hearing Adjourned to October 30
Max Healthcare: Approves 95,000 Stock Options Grant
Max Healthcare Institute 's tribunal hearing postponed to October 30, 2026
Max Healthcare NCLT hearing on Kalinga Hospital petitions adjourned
Max Healthcare: Updates on Kalinga Hospital Subsidiary Legal Proceedings
Max Healthcare Institute (NSEI:MAXHEALTH) Stock Forecast & Analyst Predictions
Max Healthcare shareholders approve new PRSU scheme and CMD remuneration
Should You Be Adding Max Healthcare Institute (NSE:MAXHEALTH) To Your Watchlist Today?